| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
143,258 |
84,875 |
$8.25M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
91,445 |
85,756 |
$2.53M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
89,678 |
84,134 |
$2.47M |
| 87806 |
|
49,802 |
37,558 |
$1.22M |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
64,351 |
34,710 |
$1.17M |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
45,936 |
40,553 |
$858K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
23,575 |
14,176 |
$846K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
25,855 |
9,279 |
$683K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
58,422 |
30,506 |
$583K |
| 80055 |
|
11,996 |
11,967 |
$380K |
| 83021 |
|
43,522 |
42,735 |
$363K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
82,322 |
76,880 |
$329K |
| 84443 |
Thyroid stimulating hormone (TSH) |
44,871 |
43,973 |
$320K |
| 80053 |
Comprehensive metabolic panel |
61,435 |
58,831 |
$293K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
24,444 |
24,021 |
$292K |
| 80061 |
Lipid panel |
46,835 |
46,085 |
$269K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
4,424 |
1,141 |
$266K |
| 86780 |
|
24,001 |
23,948 |
$261K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
836 |
682 |
$260K |
| 86481 |
|
4,712 |
4,675 |
$247K |
| 86592 |
|
64,634 |
59,663 |
$222K |
| 86003 |
|
878 |
826 |
$154K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
3,542 |
1,911 |
$136K |
| 84702 |
|
10,426 |
7,594 |
$117K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
1,427 |
1,068 |
$114K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
20,138 |
19,118 |
$88K |
| 88142 |
|
6,401 |
6,369 |
$82K |
| 87340 |
|
10,402 |
10,271 |
$76K |
| 86762 |
|
6,283 |
6,270 |
$73K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
3,179 |
3,037 |
$66K |
| 84439 |
|
16,429 |
16,196 |
$65K |
| 86803 |
|
6,272 |
6,153 |
$57K |
| 84153 |
|
6,895 |
6,754 |
$57K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
2,261 |
1,928 |
$56K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,945 |
1,779 |
$56K |
| 82607 |
|
9,724 |
9,559 |
$44K |
| 82746 |
|
6,979 |
6,906 |
$43K |
| 86235 |
|
345 |
345 |
$43K |
| 81003 |
|
33,903 |
32,462 |
$36K |
| 83880 |
|
2,823 |
2,737 |
$36K |
| 80074 |
|
1,330 |
1,301 |
$34K |
| 84403 |
|
2,099 |
2,072 |
$33K |
| 86706 |
|
4,405 |
4,321 |
$32K |
| 87081 |
|
6,286 |
5,573 |
$31K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
102 |
89 |
$30K |
| 87522 |
Neg quan hep c or qual rna |
1,018 |
1,014 |
$29K |
| S3600 |
Stat laboratory request (situations other than s3601) |
11,831 |
6,140 |
$29K |
| 82728 |
|
4,500 |
4,346 |
$28K |
| 82274 |
|
4,146 |
3,086 |
$28K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
560 |
515 |
$28K |
| 82951 |
|
2,797 |
2,612 |
$28K |
| 87077 |
|
6,182 |
5,928 |
$27K |
| 80164 |
|
3,355 |
3,136 |
$27K |
| 82570 |
|
13,525 |
10,768 |
$25K |
| 99000 |
|
7,615 |
6,898 |
$25K |
| 87486 |
|
690 |
594 |
$25K |
| 82043 |
|
10,397 |
10,253 |
$25K |
| 84466 |
|
4,207 |
4,138 |
$25K |
| 84480 |
|
3,261 |
3,247 |
$24K |
| 86038 |
|
3,696 |
3,653 |
$22K |
| 86790 |
|
2,510 |
2,454 |
$21K |
| 84550 |
|
11,301 |
10,925 |
$21K |
| 86704 |
|
2,742 |
2,695 |
$20K |
| 82785 |
|
1,421 |
1,412 |
$19K |
| 87481 |
|
542 |
534 |
$19K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
4,795 |
3,967 |
$18K |
| 87581 |
|
690 |
594 |
$18K |
| 83735 |
|
4,845 |
4,439 |
$17K |
| 86696 |
|
1,151 |
1,124 |
$16K |
| 83540 |
|
5,433 |
5,310 |
$16K |
| 87070 |
|
3,358 |
3,097 |
$16K |
| 86709 |
|
2,332 |
2,306 |
$15K |
| 82950 |
|
4,224 |
3,878 |
$15K |
| 84436 |
|
5,605 |
5,527 |
$15K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
47 |
47 |
$15K |
| 83655 |
|
1,409 |
1,404 |
$14K |
| 87631 |
|
280 |
265 |
$14K |
| 86705 |
|
1,886 |
1,861 |
$14K |
| 84481 |
|
1,982 |
1,962 |
$13K |
| 80159 |
|
931 |
737 |
$13K |
| 86140 |
|
4,463 |
4,003 |
$13K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
371 |
371 |
$12K |
| 84100 |
|
6,573 |
6,217 |
$12K |
| 86141 |
|
1,476 |
1,433 |
$12K |
| 85730 |
|
3,342 |
3,230 |
$11K |
| 86695 |
|
1,168 |
1,140 |
$11K |
| G2024 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source |
493 |
237 |
$11K |
| 86403 |
|
1,269 |
1,249 |
$11K |
| 86430 |
|
4,351 |
4,321 |
$11K |
| 87186 |
|
2,885 |
2,820 |
$11K |
| 82947 |
|
4,371 |
4,165 |
$10K |
| 85610 |
|
4,664 |
4,201 |
$10K |
| 82248 |
|
4,473 |
4,368 |
$10K |
| 85651 |
|
7,084 |
6,621 |
$9K |
| 83970 |
|
695 |
692 |
$9K |
| 84270 |
|
643 |
641 |
$9K |
| 82378 |
|
2,017 |
1,915 |
$9K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
117 |
46 |
$9K |
| 86376 |
|
772 |
763 |
$8K |
| 84146 |
|
775 |
759 |
$8K |
| 86635 |
|
370 |
370 |
$8K |
| 82977 |
|
2,480 |
2,439 |
$8K |
| 84479 |
|
2,775 |
2,744 |
$8K |
| 85027 |
|
2,583 |
2,509 |
$7K |
| 83001 |
|
658 |
645 |
$7K |
| 36415 |
Collection of venous blood by venipuncture |
14,249 |
12,694 |
$7K |
| 84154 |
|
749 |
747 |
$6K |
| 81015 |
|
8,597 |
8,366 |
$6K |
| 82670 |
|
353 |
351 |
$6K |
| 87210 |
|
2,353 |
2,349 |
$6K |
| 87184 |
|
2,004 |
1,953 |
$6K |
| 86225 |
|
448 |
447 |
$6K |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
4,885 |
4,037 |
$5K |
| 82105 |
|
298 |
289 |
$5K |
| 86901 |
|
2,349 |
2,277 |
$5K |
| 82140 |
|
726 |
685 |
$5K |
| 80178 |
|
1,204 |
1,060 |
$5K |
| 86900 |
|
2,281 |
2,277 |
$5K |
| 84134 |
|
588 |
497 |
$4K |
| 83002 |
|
412 |
409 |
$4K |
| S5102 |
Day care services, adult; per diem |
49 |
49 |
$4K |
| P9603 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled |
980 |
837 |
$4K |
| 83090 |
|
181 |
181 |
$4K |
| 80076 |
|
1,227 |
1,207 |
$4K |
| 86787 |
|
376 |
373 |
$4K |
| 85045 |
|
1,189 |
1,184 |
$4K |
| 83615 |
|
1,899 |
1,836 |
$3K |
| 88312 |
|
490 |
448 |
$3K |
| 86301 |
|
723 |
718 |
$3K |
| 83690 |
|
1,196 |
1,164 |
$3K |
| 84311 |
|
3,033 |
594 |
$3K |
| 86735 |
|
280 |
278 |
$3K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
374 |
341 |
$3K |
| 86765 |
|
280 |
278 |
$3K |
| 82150 |
|
917 |
897 |
$3K |
| 86769 |
|
99 |
50 |
$3K |
| 83525 |
|
267 |
267 |
$3K |
| 88313 |
|
463 |
421 |
$3K |
| 82465 |
|
1,013 |
998 |
$3K |
| 80177 |
|
416 |
403 |
$3K |
| 86480 |
|
58 |
58 |
$3K |
| 80051 |
|
437 |
431 |
$2K |
| 80202 |
|
261 |
130 |
$2K |
| 86677 |
|
282 |
281 |
$2K |
| 86160 |
|
69 |
68 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
275 |
181 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,546 |
3,522 |
$2K |
| 83605 |
|
353 |
352 |
$2K |
| 85007 |
|
1,340 |
1,296 |
$2K |
| 82550 |
|
1,030 |
911 |
$2K |
| 85018 |
|
1,461 |
1,411 |
$2K |
| 87147 |
|
589 |
579 |
$2K |
| 84156 |
|
460 |
446 |
$2K |
| 83986 |
|
3,099 |
594 |
$2K |
| 83516 |
|
57 |
55 |
$2K |
| 84144 |
|
108 |
108 |
$2K |
| 87150 |
|
74 |
72 |
$2K |
| 87338 |
|
60 |
59 |
$1K |
| 87529 |
|
28 |
28 |
$1K |
| 86593 |
|
401 |
399 |
$1K |
| 87536 |
|
44 |
44 |
$1K |
| 86708 |
|
156 |
152 |
$1K |
| 86039 |
|
203 |
201 |
$1K |
| 86063 |
|
495 |
494 |
$1K |
| 86304 |
|
309 |
304 |
$1K |
| 81025 |
|
391 |
385 |
$1K |
| K1034 |
Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count |
1,216 |
1,168 |
$1K |
| 84703 |
|
218 |
216 |
$1K |
| 85013 |
|
820 |
811 |
$1K |
| 84681 |
|
50 |
50 |
$800.03 |
| 87177 |
|
74 |
59 |
$737.95 |
| 83718 |
|
144 |
144 |
$649.48 |
| 82533 |
|
108 |
106 |
$590.13 |
| 84478 |
|
228 |
190 |
$572.72 |
| 86694 |
|
55 |
53 |
$530.33 |
| 87807 |
|
72 |
69 |
$529.05 |
| 86300 |
|
91 |
86 |
$502.85 |
| 86850 |
|
203 |
203 |
$485.97 |
| 87634 |
|
17 |
15 |
$477.36 |
| 99058 |
|
43 |
31 |
$477.23 |
| 86200 |
|
122 |
122 |
$351.49 |
| 84484 |
|
70 |
64 |
$289.47 |
| 82565 |
|
197 |
195 |
$287.04 |
| 82310 |
|
193 |
193 |
$284.90 |
| 84402 |
|
12 |
12 |
$246.95 |
| 87517 |
|
16 |
16 |
$222.77 |
| 80185 |
|
44 |
41 |
$205.18 |
| 84460 |
|
74 |
74 |
$171.49 |
| 82040 |
|
97 |
96 |
$157.83 |
| 84520 |
|
167 |
165 |
$157.57 |
| 84075 |
|
119 |
119 |
$152.45 |
| 80069 |
|
52 |
52 |
$132.53 |
| 84132 |
|
59 |
59 |
$131.04 |
| 86800 |
|
15 |
15 |
$122.43 |
| 86060 |
|
28 |
28 |
$120.87 |
| 80156 |
|
14 |
14 |
$112.58 |
| 85048 |
|
135 |
126 |
$107.31 |
| 84295 |
|
45 |
44 |
$99.66 |
| 82747 |
|
12 |
12 |
$87.21 |
| 85049 |
|
340 |
340 |
$82.01 |
| 85014 |
|
130 |
129 |
$68.26 |
| 84450 |
|
61 |
61 |
$64.89 |
| 83721 |
|
49 |
49 |
$57.30 |
| 87045 |
|
13 |
13 |
$53.05 |
| 86356 |
|
12 |
12 |
$47.12 |
| 82435 |
|
24 |
24 |
$38.92 |
| 87088 |
|
12 |
12 |
$29.06 |
| 82247 |
|
25 |
25 |
$19.18 |
| 84155 |
|
26 |
26 |
$18.05 |
| 88311 |
|
15 |
14 |
$7.82 |
| 82652 |
|
58 |
58 |
$0.00 |
| 83013 |
|
53 |
52 |
$0.00 |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
15 |
15 |
$0.00 |
| 3046F |
|
44 |
44 |
$0.00 |
| 3045F |
|
12 |
12 |
$0.00 |
| G2025 |
Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only |
226 |
104 |
$0.00 |
| 3044F |
|
1,642 |
1,635 |
$0.00 |